Source link : https://www.newshealth.biz/health-news/a-huge-win-for-patients-with-endometrial-cancer/
Adding an immune checkpoint inhibitor to platinum-based chemotherapy resulted in a more than 1-year gain in median overall survival for women with primary advanced or recurrent endometrial cancer. The benefit of the combination of the programmed death protein 1 (PD-1) inhibitor dostarlimab (Jemperli) and chemotherapy was even more pronounced among patients with DNA mismatch repair […]
Author : News Health
Publish date : 2024-03-19 07:31:28
Copyright for syndicated content belongs to the linked Source.